// STATE LEGISLATION TRACKER

Kentucky HB 896 — AN ACT relating to hemp products and declaring an emergency.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Kentucky
Bill: HB 896
Filed: 2026-03-04
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Kentucky HB896 appears to be about hemp products, not peptide drugs, compounding, prescribing, telehealth, clinician scope, controlled substances, or prescription monitoring. Based only on the title, subjects, and unavailable latest-action data, it does not appear to change access to compounded peptides or off-label peptide prescribing.

Key Points

No clear impact on compounded peptides
No clear change to off-label prescribing
No telehealth or clinician-scope signal in the title
No FDA 503A/503B compounding signal
Hemp-product rules may affect cannabinoid products only

What to Watch For

Note Confirm bill text when available; current source data does not show peptide-specific provisions.

Note Watch whether later amendments add pharmacy, compounding, prescribing, or controlled-substance language.

Where the Bill Stands

The OpenStates source did not provide a current latest action, so the bill's exact position in the process is unknown.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws